These KRAS alterations have been identified in 25% of all cancers, such as blood, breast, colorectal, gynecological, lung, prostate, and pancreatic cancer, in which some cancers, pancreatic cancer (90%), colorectal cancer (52%), and lung adenocarcinoma (32%) have extremely high mutation rates (Mustachio et al., 2021). This evidence concerns the gene KRAS and pancreatic neoplasm.